페니실린계 항균제 시장 : 유래별, 투여 경로별, 항균 스펙트럼별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2023-2032년)

The penicillin drug market is likely to experience a significant growth rate of 3.7% from 2023-2032 owing to increasing market demand from pharmaceutical sector - Allied Market Research.

"The COVID-19 pandemic had a slight positive impact on the penicillin market as it heightened the importance of effective infection control measures and the need for appropriate antibiotic treatment. Additionally, the increased awareness about respiratory infections during the pandemic led to a surge in demand for penicillin drugs, contributing to market growth."

Market Dynamics

The penicillin drug market size is experiencing significant growth due to various driving factors including the prevalence of bacterial infections which plays a crucial role in the increased demand for penicillin. Bacterial infections are a common healthcare concern globally, which includes skin infection, dental infection, ear infection, an infection of the nose, throat or lungs, urinary tract infection and other bacterial infections.

For instance, According to National Center for Health Statistics (NCHS), there were 1.5 million number of visits to emergency departments with pneumonia as the primary diagnosis in U.S. Such huge prevalence of pneumonia and other respiratory tract infections is contributing to the growth of the market. As penicillin, as an effective and well-established antibiotic, remains a frontline treatment option for many bacterial infections. The rising incidence of these infections, both in community and healthcare settings, necessitates the use of penicillin and drives the penicillin drug market growth.

In addition, advancements in healthcare infrastructure and access to healthcare services play a significant role in driving penicillin drug market share. Improved healthcare facilities, especially in developing countries, have led to better diagnosis and management of bacterial infections. As healthcare systems strengthen, the availability and accessibility of penicillin are enhanced, leading to increased utilization and market growth.

Furthermore, the growing awareness about the importance of appropriate antibiotic use among healthcare providers and patients has contributed to the demand for penicillin in penicillin drug market forecast period. With increased knowledge about the appropriate indications, dosing, and duration of penicillin therapy, healthcare professionals are more likely to prescribe it when appropriate, promoting its market growth. Patients also play a vital role in driving market growth by seeking timely medical attention for bacterial infections and following the prescribed penicillin regimen.

While there are several driving factors for the growth of the penicillin market, the rising antimicrobial resistance (AMR) indeed acts as a significant restraint to its growth. Antimicrobial resistance refers to the ability of bacteria to survive and multiply despite the presence of antibiotics, leading to the reduced effectiveness of these medications. AMR poses a considerable challenge to the treatment of bacterial infections, including those that penicillin is commonly used to treat. Antimicrobial resistance leads to reduced efficacy, need for alternative treatments, and increased healthcare costs, which may hinder the growth of the penicillin market.

However, R&D efforts in the pharmaceutical industry are anticipated to overcome this challenge. Addressing antimicrobial resistance requires a multi-faceted approach, including improved infection prevention measures, optimized antibiotic use, and the development of novel antimicrobial agents. Thus, pharmaceutical companies are recognizing the importance of continually improving and expanding the options available for penicillin therapy, which is anticipated to boost the penicillin market growth during the forecast period.

In addition, companies are investing on a large scale to create alternative formulations that offer advantages such as improved pharmacokinetics, or better patient tolerability of penicillin medications. For instance, in November 2022, Sandoz, a global pharmaceutical company, announced plans for a significant investment in one of its key manufacturing facilities in Austria. The company aims to address the increased global demand for essential antibiotics, specifically finished dosage form penicillin, which are considered the leading class of antibiotics worldwide. The planned investment amounts to EUR 50 million and is focused on expanding the manufacturing capacity for penicillin antibiotics.

In addition, the surge in demand for affordable and generic penicillin medication is playing a pivotal role in boosting the growth of the market. Generic medications, including generic penicillin, offer a more cost-effective alternative to their brand-name counterparts, making them increasingly sought after by patients and healthcare systems. The availability of multiple manufacturers producing generic penicillin has also led to increased market competition, resulting in lower prices and a steady supply of medications. This contributed to the growth of the global penicillin drug market.

The covid-19 pandemic had a slight positive impact on the penicillin drug market. An article by National Center for Biotechnology Information (NCBI) in 2022, stated that COVID-19 pandemic led to increased self-medication of antimicrobials, vitamins, and immune boosters among the people. This led to an increased demand for penicillin and other antibiotics during the pandemic and contributed to market growth.

On the other hand, the global supply chains for pharmaceutical products experienced disruptions due to lockdowns, travel restrictions, and increased demand. These challenges impacted the availability of raw materials and finished products, including penicillin. However, the market is anticipated to normalize in the coming years as there have been surge in investment to meet the increasing demand for penicillin in the market.

Segmental Overview

The global penicillin drug market is segmented on the basis of source, route of administration, distribution channel and region. On the basis of source, the market is categorized as natural penicillin and semisynthetic penicillin. The Semisynthetic penicillin segment is further segmented into aminopenicillin, penicillinase-resistant penicillin and others. Based on spectrum of activity, the narrow spectrum penicillin, broad spectrum penicillin, and extended spectrum penicillin. On the basis of route of administration, it is bifurcated into oral and parenteral.

Based on the distribution channel the market is segmented into hospital pharmacies, drug stores and retail pharmacies and online providers. Based on region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Key Benefits For Stakeholders:

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the penicillin drug market analysis from 2022 to 2032 to identify the prevailing penicillin drug market opportunity.

• The market research is offered along with information related to key drivers, restraints, and opportunities.

• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

• In-depth analysis of the penicillin drug market segmentation assists to determine the prevailing market opportunities.

• Major countries in each region are mapped according to their revenue contribution to the global market.

• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

• The report includes the analysis of the regional as well as global penicillin drug market trends, key players, market segments, application areas, and market growth strategies.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Bargaining power of suppliers
  • 3.3.2. Bargaining power of buyers
  • 3.3.3. Threat of substitutes
  • 3.3.4. Threat of new entrants
  • 3.3.5. Intensity of rivalry
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Surge in awareness and adoption of combination medication
    • 3.4.1.2. Rise in incidences of bacterial infections
    • 3.4.1.3. Availability of generic medications

• 3.4.2. Restraints
  • 3.4.2.1. Side effects associated with penicillin
  • 3.4.2.2. Increase in Resistance to Anti-microbials

• 3.4.3. Opportunities
  • 3.4.3.1. Rise in investments in R&D activities

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PENICILLIN DRUG MARKET, BY SOURCE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Natural penicillin
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Semisynthetic penicillin
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
  • 4.3.4. Semisynthetic penicillin Penicillin Drug Market by Class

CHAPTER 5: PENICILLIN DRUG MARKET, BY ROUTE OF ADMINISTRATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Oral
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Parenteral
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: PENICILLIN DRUG MARKET, BY SPECTRUM OF ACTIVITY

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Narrow spectrum penicillin
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Broad spectrum penicillin
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Extended spectrum penicillin
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: PENICILLIN DRUG MARKET, BY DISTRIBUTION CHANNEL

• 7.1. Overview
  • 7.1.1. Market size and forecast
• 7.2. Hospital Pharmacies
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by region
  • 7.2.3. Market share analysis by country
• 7.3. Drug Stores and Retail Pharmacies
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by region
  • 7.3.3. Market share analysis by country
• 7.4. Online Providers
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by region
  • 7.4.3. Market share analysis by country

CHAPTER 8: PENICILLIN DRUG MARKET, BY REGION

• 8.1. Overview
  • 8.1.1. Market size and forecast By Region
• 8.2. North America
  • 8.2.1. Key trends and opportunities
  • 8.2.2. Market size and forecast, by Source
  • 8.2.3. Market size and forecast, by Route of Administration
  • 8.2.4. Market size and forecast, by Spectrum of Activity
  • 8.2.5. Market size and forecast, by Distribution Channel
  • 8.2.6. Market size and forecast, by country
    • 8.2.6.1. U.S.
    • 8.2.6.1.1. Key market trends, growth factors and opportunities
    • 8.2.6.1.2. Market size and forecast, by Source
    • 8.2.6.1.3. Market size and forecast, by Route of Administration
    • 8.2.6.1.4. Market size and forecast, by Spectrum of Activity
    • 8.2.6.1.5. Market size and forecast, by Distribution Channel
    • 8.2.6.2. Canada
    • 8.2.6.2.1. Key market trends, growth factors and opportunities
    • 8.2.6.2.2. Market size and forecast, by Source
    • 8.2.6.2.3. Market size and forecast, by Route of Administration
    • 8.2.6.2.4. Market size and forecast, by Spectrum of Activity
    • 8.2.6.2.5. Market size and forecast, by Distribution Channel
    • 8.2.6.3. Mexico
    • 8.2.6.3.1. Key market trends, growth factors and opportunities
    • 8.2.6.3.2. Market size and forecast, by Source
    • 8.2.6.3.3. Market size and forecast, by Route of Administration
    • 8.2.6.3.4. Market size and forecast, by Spectrum of Activity
    • 8.2.6.3.5. Market size and forecast, by Distribution Channel
• 8.3. Europe
  • 8.3.1. Key trends and opportunities
  • 8.3.2. Market size and forecast, by Source
  • 8.3.3. Market size and forecast, by Route of Administration
  • 8.3.4. Market size and forecast, by Spectrum of Activity
  • 8.3.5. Market size and forecast, by Distribution Channel
  • 8.3.6. Market size and forecast, by country
    • 8.3.6.1. Germany
    • 8.3.6.1.1. Key market trends, growth factors and opportunities
    • 8.3.6.1.2. Market size and forecast, by Source
    • 8.3.6.1.3. Market size and forecast, by Route of Administration
    • 8.3.6.1.4. Market size and forecast, by Spectrum of Activity
    • 8.3.6.1.5. Market size and forecast, by Distribution Channel
    • 8.3.6.2. France
    • 8.3.6.2.1. Key market trends, growth factors and opportunities
    • 8.3.6.2.2. Market size and forecast, by Source
    • 8.3.6.2.3. Market size and forecast, by Route of Administration
    • 8.3.6.2.4. Market size and forecast, by Spectrum of Activity
    • 8.3.6.2.5. Market size and forecast, by Distribution Channel
    • 8.3.6.3. UK
    • 8.3.6.3.1. Key market trends, growth factors and opportunities
    • 8.3.6.3.2. Market size and forecast, by Source
    • 8.3.6.3.3. Market size and forecast, by Route of Administration
    • 8.3.6.3.4. Market size and forecast, by Spectrum of Activity
    • 8.3.6.3.5. Market size and forecast, by Distribution Channel
    • 8.3.6.4. Italy
    • 8.3.6.4.1. Key market trends, growth factors and opportunities
    • 8.3.6.4.2. Market size and forecast, by Source
    • 8.3.6.4.3. Market size and forecast, by Route of Administration
    • 8.3.6.4.4. Market size and forecast, by Spectrum of Activity
    • 8.3.6.4.5. Market size and forecast, by Distribution Channel
    • 8.3.6.5. Spain
    • 8.3.6.5.1. Key market trends, growth factors and opportunities
    • 8.3.6.5.2. Market size and forecast, by Source
    • 8.3.6.5.3. Market size and forecast, by Route of Administration
    • 8.3.6.5.4. Market size and forecast, by Spectrum of Activity
    • 8.3.6.5.5. Market size and forecast, by Distribution Channel
    • 8.3.6.6. Rest of Europe
    • 8.3.6.6.1. Key market trends, growth factors and opportunities
    • 8.3.6.6.2. Market size and forecast, by Source
    • 8.3.6.6.3. Market size and forecast, by Route of Administration
    • 8.3.6.6.4. Market size and forecast, by Spectrum of Activity
    • 8.3.6.6.5. Market size and forecast, by Distribution Channel
• 8.4. Asia-Pacific
  • 8.4.1. Key trends and opportunities
  • 8.4.2. Market size and forecast, by Source
  • 8.4.3. Market size and forecast, by Route of Administration
  • 8.4.4. Market size and forecast, by Spectrum of Activity
  • 8.4.5. Market size and forecast, by Distribution Channel
  • 8.4.6. Market size and forecast, by country
    • 8.4.6.1. Japan
    • 8.4.6.1.1. Key market trends, growth factors and opportunities
    • 8.4.6.1.2. Market size and forecast, by Source
    • 8.4.6.1.3. Market size and forecast, by Route of Administration
    • 8.4.6.1.4. Market size and forecast, by Spectrum of Activity
    • 8.4.6.1.5. Market size and forecast, by Distribution Channel
    • 8.4.6.2. China
    • 8.4.6.2.1. Key market trends, growth factors and opportunities
    • 8.4.6.2.2. Market size and forecast, by Source
    • 8.4.6.2.3. Market size and forecast, by Route of Administration
    • 8.4.6.2.4. Market size and forecast, by Spectrum of Activity
    • 8.4.6.2.5. Market size and forecast, by Distribution Channel
    • 8.4.6.3. India
    • 8.4.6.3.1. Key market trends, growth factors and opportunities
    • 8.4.6.3.2. Market size and forecast, by Source
    • 8.4.6.3.3. Market size and forecast, by Route of Administration
    • 8.4.6.3.4. Market size and forecast, by Spectrum of Activity
    • 8.4.6.3.5. Market size and forecast, by Distribution Channel
    • 8.4.6.4. Australia
    • 8.4.6.4.1. Key market trends, growth factors and opportunities
    • 8.4.6.4.2. Market size and forecast, by Source
    • 8.4.6.4.3. Market size and forecast, by Route of Administration
    • 8.4.6.4.4. Market size and forecast, by Spectrum of Activity
    • 8.4.6.4.5. Market size and forecast, by Distribution Channel
    • 8.4.6.5. South Korea
    • 8.4.6.5.1. Key market trends, growth factors and opportunities
    • 8.4.6.5.2. Market size and forecast, by Source
    • 8.4.6.5.3. Market size and forecast, by Route of Administration
    • 8.4.6.5.4. Market size and forecast, by Spectrum of Activity
    • 8.4.6.5.5. Market size and forecast, by Distribution Channel
    • 8.4.6.6. Rest of Asia-Pacific
    • 8.4.6.6.1. Key market trends, growth factors and opportunities
    • 8.4.6.6.2. Market size and forecast, by Source
    • 8.4.6.6.3. Market size and forecast, by Route of Administration
    • 8.4.6.6.4. Market size and forecast, by Spectrum of Activity
    • 8.4.6.6.5. Market size and forecast, by Distribution Channel
• 8.5. LAMEA
  • 8.5.1. Key trends and opportunities
  • 8.5.2. Market size and forecast, by Source
  • 8.5.3. Market size and forecast, by Route of Administration
  • 8.5.4. Market size and forecast, by Spectrum of Activity
  • 8.5.5. Market size and forecast, by Distribution Channel
  • 8.5.6. Market size and forecast, by country
    • 8.5.6.1. Brazil
    • 8.5.6.1.1. Key market trends, growth factors and opportunities
    • 8.5.6.1.2. Market size and forecast, by Source
    • 8.5.6.1.3. Market size and forecast, by Route of Administration
    • 8.5.6.1.4. Market size and forecast, by Spectrum of Activity
    • 8.5.6.1.5. Market size and forecast, by Distribution Channel
    • 8.5.6.2. Saudi Arabia
    • 8.5.6.2.1. Key market trends, growth factors and opportunities
    • 8.5.6.2.2. Market size and forecast, by Source
    • 8.5.6.2.3. Market size and forecast, by Route of Administration
    • 8.5.6.2.4. Market size and forecast, by Spectrum of Activity
    • 8.5.6.2.5. Market size and forecast, by Distribution Channel
    • 8.5.6.3. South Africa
    • 8.5.6.3.1. Key market trends, growth factors and opportunities
    • 8.5.6.3.2. Market size and forecast, by Source
    • 8.5.6.3.3. Market size and forecast, by Route of Administration
    • 8.5.6.3.4. Market size and forecast, by Spectrum of Activity
    • 8.5.6.3.5. Market size and forecast, by Distribution Channel
    • 8.5.6.4. Rest of LAMEA
    • 8.5.6.4.1. Key market trends, growth factors and opportunities
    • 8.5.6.4.2. Market size and forecast, by Source
    • 8.5.6.4.3. Market size and forecast, by Route of Administration
    • 8.5.6.4.4. Market size and forecast, by Spectrum of Activity
    • 8.5.6.4.5. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

• 9.1. Introduction
• 9.2. Top winning strategies
• 9.3. Product Mapping of Top 10 Player
• 9.4. Competitive Dashboard
• 9.5. Competitive Heatmap
• 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

• 10.1. GlaxoSmithKline plc
  • 10.1.1. Company overview
  • 10.1.2. Key Executives
  • 10.1.3. Company snapshot
  • 10.1.4. Operating business segments
  • 10.1.5. Product portfolio
  • 10.1.6. Business performance
  • 10.1.7. Key strategic moves and developments
• 10.2. Pfizer Inc.
  • 10.2.1. Company overview
  • 10.2.2. Key Executives
  • 10.2.3. Company snapshot
  • 10.2.4. Operating business segments
  • 10.2.5. Product portfolio
  • 10.2.6. Business performance
• 10.3. Novartis AG
  • 10.3.1. Company overview
  • 10.3.2. Key Executives
  • 10.3.3. Company snapshot
  • 10.3.4. Operating business segments
  • 10.3.5. Product portfolio
  • 10.3.6. Business performance
  • 10.3.7. Key strategic moves and developments
• 10.4. Lupin
  • 10.4.1. Company overview
  • 10.4.2. Key Executives
  • 10.4.3. Company snapshot
  • 10.4.4. Operating business segments
  • 10.4.5. Product portfolio
  • 10.4.6. Business performance
• 10.5. Abbott Laboratories
  • 10.5.1. Company overview
  • 10.5.2. Key Executives
  • 10.5.3. Company snapshot
  • 10.5.4. Operating business segments
  • 10.5.5. Product portfolio
  • 10.5.6. Business performance
• 10.6. Cipla Ltd
  • 10.6.1. Company overview
  • 10.6.2. Key Executives
  • 10.6.3. Company snapshot
  • 10.6.4. Operating business segments
  • 10.6.5. Product portfolio
  • 10.6.6. Business performance
• 10.7. Takeda Pharmaceutical Company Ltd
  • 10.7.1. Company overview
  • 10.7.2. Key Executives
  • 10.7.3. Company snapshot
  • 10.7.4. Operating business segments
  • 10.7.5. Product portfolio
  • 10.7.6. Business performance
• 10.8. Alkem Laboratories Ltd.
  • 10.8.1. Company overview
  • 10.8.2. Key Executives
  • 10.8.3. Company snapshot
  • 10.8.4. Operating business segments
  • 10.8.5. Product portfolio
  • 10.8.6. Business performance
• 10.9. Teva Pharmaceutical Industries Limited
  • 10.9.1. Company overview
  • 10.9.2. Key Executives
  • 10.9.3. Company snapshot
  • 10.9.4. Operating business segments
  • 10.9.5. Product portfolio
  • 10.9.6. Business performance
• 10.10. SUN PHARMACEUTICAL INDUSTRIES LIMITED
  • 10.10.1. Company overview
  • 10.10.2. Key Executives
  • 10.10.3. Company snapshot
  • 10.10.4. Operating business segments
  • 10.10.5. Product portfolio
  • 10.10.6. Business performance